Glenmark Cleared By FDA to Market Generic Pravachol

Mumbai-based Glenmark Pharmaceuticals has received FDA approval to market pravastatin sodium tablets 10mg, 20mg and 40mg, a generic version of Bristol-Myers Squibb’s statin Pravachol.

Pravachol, a cholesterol-lowering drug, has annual sales of over $861 million, according to Glenmark. The generics company said that it is manufacturing the formulation in its facility in Goa, India.

Last month, Glenmark also received US FDA approval to market naproxen sodium tablets, a generic version of Roche’s brand Anaprox and naproxen tablets, a generic version of Roche’s brand Naprosyn.